Controlling AIDS in Cuba

Antonio M. Gordon, Reinaldo Paya, Cheryl Healton, Ronald Bayer

Research output: Contribution to journalLetter

Abstract

To the Editor: The Special Report by Bayer and Healton (April 13 issue)1 on the acquired immunodeficiency syndrome (AIDS) in Cuba raises questions that should be considered in the light of the available information. Indeed, Cuba's approach to AIDS control is unique. It does not emphasize education, it has screened about 4 million persons and plans to screen the entire population of the island, and it has reported a seropositive rate that is comparable to that of Oklahoma. How a Caribbean island with a 500 percent increase in gonorrhea in the past 10 years,2 a contingent of 380,000 in Africa….

Original languageEnglish (US)
Pages (from-to)829-830
Number of pages2
JournalNew England Journal of Medicine
Volume321
Issue number12
DOIs
StatePublished - Sep 21 1989

Fingerprint

Cuba
Acquired Immunodeficiency Syndrome
West Indies
Gonorrhea
Islands
Education
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Controlling AIDS in Cuba. / Gordon, Antonio M.; Paya, Reinaldo; Healton, Cheryl; Bayer, Ronald.

In: New England Journal of Medicine, Vol. 321, No. 12, 21.09.1989, p. 829-830.

Research output: Contribution to journalLetter

Gordon, AM, Paya, R, Healton, C & Bayer, R 1989, 'Controlling AIDS in Cuba', New England Journal of Medicine, vol. 321, no. 12, pp. 829-830. https://doi.org/10.1056/NEJM198909213211212
Gordon, Antonio M. ; Paya, Reinaldo ; Healton, Cheryl ; Bayer, Ronald. / Controlling AIDS in Cuba. In: New England Journal of Medicine. 1989 ; Vol. 321, No. 12. pp. 829-830.
@article{cef9e8008b9b45d7aaac5fd350965e4a,
title = "Controlling AIDS in Cuba",
abstract = "To the Editor: The Special Report by Bayer and Healton (April 13 issue)1 on the acquired immunodeficiency syndrome (AIDS) in Cuba raises questions that should be considered in the light of the available information. Indeed, Cuba's approach to AIDS control is unique. It does not emphasize education, it has screened about 4 million persons and plans to screen the entire population of the island, and it has reported a seropositive rate that is comparable to that of Oklahoma. How a Caribbean island with a 500 percent increase in gonorrhea in the past 10 years,2 a contingent of 380,000 in Africa….",
author = "Gordon, {Antonio M.} and Reinaldo Paya and Cheryl Healton and Ronald Bayer",
year = "1989",
month = "9",
day = "21",
doi = "10.1056/NEJM198909213211212",
language = "English (US)",
volume = "321",
pages = "829--830",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "12",

}

TY - JOUR

T1 - Controlling AIDS in Cuba

AU - Gordon, Antonio M.

AU - Paya, Reinaldo

AU - Healton, Cheryl

AU - Bayer, Ronald

PY - 1989/9/21

Y1 - 1989/9/21

N2 - To the Editor: The Special Report by Bayer and Healton (April 13 issue)1 on the acquired immunodeficiency syndrome (AIDS) in Cuba raises questions that should be considered in the light of the available information. Indeed, Cuba's approach to AIDS control is unique. It does not emphasize education, it has screened about 4 million persons and plans to screen the entire population of the island, and it has reported a seropositive rate that is comparable to that of Oklahoma. How a Caribbean island with a 500 percent increase in gonorrhea in the past 10 years,2 a contingent of 380,000 in Africa….

AB - To the Editor: The Special Report by Bayer and Healton (April 13 issue)1 on the acquired immunodeficiency syndrome (AIDS) in Cuba raises questions that should be considered in the light of the available information. Indeed, Cuba's approach to AIDS control is unique. It does not emphasize education, it has screened about 4 million persons and plans to screen the entire population of the island, and it has reported a seropositive rate that is comparable to that of Oklahoma. How a Caribbean island with a 500 percent increase in gonorrhea in the past 10 years,2 a contingent of 380,000 in Africa….

UR - http://www.scopus.com/inward/record.url?scp=0024434020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024434020&partnerID=8YFLogxK

U2 - 10.1056/NEJM198909213211212

DO - 10.1056/NEJM198909213211212

M3 - Letter

C2 - 2770814

AN - SCOPUS:0024434020

VL - 321

SP - 829

EP - 830

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 12

ER -